本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。 關閉
HO CHI MINH CITY, VIETNAM – Media OutReach Newswire – 4 November 2024 - Ho Chi Minh City Development Joint Stock Commercial Bank (HDBank - Stock code: HDB) announces its 9 months business results with profit before tax reaching VND 12,655 billion (US$500 million), an increase of 46.6% year-on-year, achieving 79.8% of the full-year targets. HDBank achieved a strong ROE of 26.7% and an ROA of 2.2%, placing it among the leading banks in the sector. HDBank continued its track record of regular dividend payouts by implementing a 30% dividend for 2023. This included a 10% cash dividend paid in July, and the Bank is now finalizing the procedures for a 20% stock dividend. This positive business performance reaffirms HDBank's position among the top universal banks with a solid foundation, strong financial health, and ability to maintain high and continuous growth for many consecutive years, with good profitability ratios. HD SAISON, the consumer finance arm of HDBank, continued its strong recovery, with its loan book growing 15% YoY. Profit before tax surged by 126% to reach VND 906 billion (US$35.8 million), achieving an ROE of 22.9%, making it one of the most profitable consumer finance company in the sector. As of September 30, 2024, HDBank reported total consolidated assets of VND 629 trillion ($24.8 billion), reflecting a YoY increase of 23.9%. Similarly, total funding mobilization reached VND 559 trillion ($22 billion), demonstrating a 24.8% rise YoY. The Bank also recorded a total outstanding loan balance of VND 412 trillion (16 billion), marking a 16.6% increase since the beginning of the year. HDBank strategically directs credit flows towards key sectors driving economic growth, including rural agriculture, small and medium enterprises (SMEs), value-chain finance, household businesses, traders, and green credit initiatives. The non-performing loan ratio as prescribed by the State Bank is only 1.46%, lower than the sector average; Capital Adequacy ratio (CAR) of 14.8% under Basel II standards. Other prudential indicators are at healthy levels, demonstrating the effectiveness of HDBank's sustainable development strategy, which comprehensively integrates ESG factors. With these positive results over the first nine months, HDBank has solidified its position among leading banks in the sector. The Bank is well-positioned to maintain high and continuous growth, ensuring the successful completion of the General Meeting of Shareholders' plan.Hashtag: #HDBankThe issuer is solely responsible for the content of this announcement.
Challenges traditional view of transition from nomadic pastoralism to nascent urbanism ALULA, Saudi Arabia, Nov. 2, 2024 /PRNewswire/ -- New archaeological research has revealed an exceptional Bronze Age town in the Khaybar oasis of northwest Arabia, confirming a major transition from mobile, nomadic life to settled, town life in the second half of the third millennium BCE. The finding infers that oases such as Khaybar were carefully controlled and valued landscapes that, with the advent of agriculture, supported permanent populations as centres for exchange and interaction with mobile communities. This nascent urbanism profoundly impacted the region's socio-economic organisation. Fig. 14: A 3D virtual reconstruction of the Bronze Age town of al-Natah, based on newly published archaeological evidence. Khaybar LDAP (CNRS-AFALULA-RCU) Known as al-Natah, the newly discovered town provides evidence for differentiated functional areas – residential and funerary – within fortifications. Al-Natah was built around 2400-2000 BCE and endured until 1500-1300 BCE. Home to some 500 people across 2.6 hectares, it was protected by a stone rampart that encircled the Khaybar oasis. People in al-Natah lived in dwellings with the ground floor possibly used for storage, with living spaces above. They walked along narrow streets and buried their dead in stepped tower tombs. They prepared food with mortar and pestle, made and traded pottery, and travelled extensively. They worked metals, grew cereals, and raised animals. His Highness Prince Badr bin Abdullah bin Mohammed bin Farhan Al Saud, Governor of the Royal Commission for AlUla and Minister of Culture for Saudi Arabia, stated: "This important archaeological discovery highlights the Kingdom's global significance in the field of archaeology and confirms the depth of civilisation that the land holds. This discovery reinforces the Kingdom's efforts in protecting cultural and historical heritage and emphasises the importance of exchanging knowledge and expertise with the world to enhance awareness of our shared human heritage." His Highness added, "This discovery confirms the Kingdom's commitment to preserving the world's heritage and promoting cultural heritage in accordance with the provisions of Saudi Vision 2030. It also highlights the importance of strengthening international partnerships to present this rich legacy to future generations and the world." The discovery was led by Dr Guillaume Charloux of the Khaybar Longue Durée Archaeological Project and the French National Centre for Scientific Research (CNRS), and includes Saudis from the Royal Commission for AlUla (RCU), Dr Munirah Almushawh, a co-director of the project, and Saifi Alshilali, a historian and a member of the local community in Khaybar. The research was sponsored by the RCU and the French Agency for the Development of AlUla (AFALULA). RCU's Archaeology, Collections and Conservation team is directing an ambitious archaeological research programme in AlUla. The discovery furthers the emergence of AlUla and Saudi Arabia as global centres for archaeological research and intercultural dialogue. By commissioning and championing revelatory research on past human activity, RCU is demonstrating its archaeological leadership and responsible custodianship of cultural heritage. Published in the peer-reviewed journal PLOS One, the research challenges the picture of mobile pastoral-nomadism as the dominant economic and social way of life of northwest Arabia in the Early and Middle Bronze Ages. Dr Charloux, stated: "Our discovery challenges the model of northwest Arabia in the Bronze Age. Al-Natah confirms that rural urbanism arose earlier than believed, making it possible to consider the complexity of a sedentary settlement in a walled Bronze Age oasis." During the coming autumn fieldwork season, RCU is supporting 10 archaeological projects comprising more than 100 archaeologists and associated specialists in AlUla County and Khaybar. The article can be found here: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0309963 For an image gallery and captions, including a rendering of what al-Natah might have looked like, visit: https://drive.google.com/drive/folders/1_Jbw6gbmTHGG27DGtdyMcVwxc-M8y_k4 Fig. 7: The residential area of the al-Natah site, looking west. Khaybar LDAP (CNRS-AFALULA-RCU)
Survey: 77% Local Consumers Agree AI Brings Shopping Convenience, Over Half of Them are Concerned about Lack of Interactivity and Data Privacy GS1 HK's First-eve "Digital Transformation Award" Results Unveiled HONG KONG, Nov. 1, 2024 /PRNewswire/ -- The GS1 HK Summit 2024 ("the Summit") was held successfully today at the HK Convention & Exhibition Centre attracting about 650 cross-industry participants' registrations from Hong Kong and the Asia Pacific region. A session at the Summit featured GS1 and KPMG jointly announcing the results of a consumer survey in the Asia-Pacific region, as well as latest survey data on local consumers' views on artificial intelligence (AI) and retail. Co-located at the event, the first "Digital Transformation Awards" presentation ceremony handed out 23 awards to companies that have successfully implemented digital transformation initiatives. (left to right) Duncan Chiu, Legislative Councillor; Frankie Yick, Legislative Councillor; Zhou Qiang, Deputy Director-General of Economic Affairs & Head of Commercial Office, LOCPG in the HKSAR; May Chung, Chairman, GS1 Hong Kong; Lam Sai-hung, Secretary for Transport and Logistics; Renaud de Barbuat, President and CEO, GS1; Jeffrey Lam, Executive Council & Legislative Councillor; Peter Shiu, Member of the 14th CPPCC National Committee and Legislative Councillor; Anna Lin, CE, GS1 HK Themed "Transforming for the Next Generation Commerce", the Summit was inaugurated by Guest of Honour Mr. Lam Sai Hung, Secretary for Transport and Logistics of the HKSAR Government, who delivered the opening address. "Digitalisation in trade and logistics is indeed an irreversible trend. With the surge in cargo volume and the increasing emphasis on prompt delivery, logistics going digital is a must, not an option. The Government therefore spares no efforts in providing all assistance to the trade to ride the tide of digitalisation to stay in the game." Ms. May Chung, Chairman of GS1 Hong Kong said in her welcome address that the theme "next generation" resonated with the new thinking in today's changing market environment, for example the Government's advocacy on a host of new economic drivers like low altitude economy and silver economy, and the various initiatives that support SMEs, including the Digital Transformation Support Pilot Programme. She added that GS1 HK has been evolving on and beyond its 35th anniversary, which includes the introduction of 1QR, a QR code that connects consumers to diverse information covering product specification, offers, nutrition, certification information etc.; the launch of digital trade financing solution that is built on the trusted trade data over B2B e-commerce community platform "ezTRADE", designed to relive SMEs' cash-flow; and the smart operations solution enabled by IoT technologies and traceability platform ezTRACK, to realise supply chain visibility. One of the highlights of the Summit was the unveiling of GS1 and KMPG China's survey report titled "Navigating the future of seamless commerce in Asia Pacific", which collected feedback from 7,000 consumers in 14 economies on their shopping attitudes and expectations, uncovering the latest retail trends. Full report here: https://www.gs1hk.org/sites/default/files/publications/FINAL_navigating-the-future-of-seamless-commerce-in-asia-pacific.pdf The session also released new data on consumers' sentiments on artificial intelligence (AI) applications: Among 1,075 local respondents surveyed which is conducted by YouGov, 77% recognised the convenience of using AI as a significant benefit, which include bringing 24/7 anytime, anywhere availability (59%) and faster service (52%) to their shopping experience. AI can also help save money (49%) and provide personalised recommendations (38%). 60% of respondents also agreed that AI can improve pre-purchase experience (e.g. evaluating options), at-the-point-of-purchase (43%, e.g. completing a transaction) and after-sales services (45%, e.g. customer support). Only 12% said it was not helpful; and the majority (82%) expect AI will change retail experience in the next 5 years. However, they are concerned about the lack of human interaction (59%), data privacy (54%) and AI making mistakes (54%). (The survey details: https://gs1hongkong.box.com/s/famu36oebzlu954jdjwx362kzli673lv) "Today's technology enables companies to better serve consumers and to reach a wide range of customers," said Anson Bailey, Head of Consumer & Retail KPMG Asia Pacific. "Proactively making moves to technologies and digital platforms by offering a more integrated experience, and increasing seamless shopping experiences and value to consumers can improve returns for businesses." Anna Lin, Chief Executive of GS1 HK, highlights the importance of reliability in AI data: "More and more organisations are using technologies like Internet of Things (IoT) sensors and QR codes to collect massive amounts of data, and combine AI analytics to discover industry trends and insights. Standardised, quality data is the key, as the saying goes 'Garbage In, Garbage Out', so the accuracy and credibility of AI results are directly related to the quality of the input data. This is the foundation for AI to actually realise any business benefits." GS1 HK's Digital Transformation Awards aims to recognise businesses that have successfully implemented digital transformation initiatives, leveraging technology to drive innovation, efficiency, and growth. The Awards had attracted an impressive turnout in all 9 award categories, including customer experience excellence, fintech implementation, innovation in ESG, operational excellence, people & culture, sales & marketing, supply chain & logistics, rising star of the year and digital transformation enterprise of the year. PARKnSHOP won the grand award with its seamless O+O(offline and online) retail strategy and the launch of PNS online business fulfilment centre driving robust growth. (Please refer to appendix for the list of "Digital Transformation Awards" winners.) Anna congratulated all the winning and participating companies, and thanked the judging panel for their tremendous efforts: "The winners show not only their digital prowess but also exemplify how companies can unlock the power of digital technologies, which is conducive to the development of Hong Kong's innovation and technology ecosystem and digital economy." Download link for photos: https://gs1hongkong.box.com/s/yyqihnr4jvl0b5bqy8dkoamd7at3vtad Appendix Digital Transformation Awards Winners List (in alphabetical order): Customer Experience Excellence through Digital Transformation Name of Entry HKT CX Reimagined: Leveraging Digital to Drive Exceptional Experiences MTR Corporation MTR Digital Transformation: Smart and Inclusive Journey Sleekflow Technologies Limited & Bowtie Life Insurance Company Limited Customer Experience Excellence - Bowtie Insurance Boosts Customer Engagement With SleekFlow FinTech Implementation Excellence through Digital Transformation Name of Entry Check Point Software Technologies Limited Secure By Design Yuhu Technology Limited Yuhu Supply Chain Management Solutions for Frozen Food Trade Finance Innovation in ESG through Digital Transformation Name of Entry LEE KUM KEE Lee Kum Kee Energy Management System Upgrade Maxim's Group SmartOps Paperless Transformation MTR Corporation Smart ESG: Technology-enabled Social Inclusion Project Operational Excellence through Digital Transformation Name of Entry CUHK Medical Centre Enhancing Patient Safety and Operational Efficiency through Internet of Things and Real-Time Location Services at CUHK Medical Centre DFI Retail Group (Group Digital) DFI Operation Management System HKT Streamlined Synergy: Integrating Digital Solutions for Operational Prowess People & Culture Excellence through Digital Transformation Name of Entry HKT Powering People Excellence with Digital Advancements Swire Coca-Cola HK AI for Traffic Safety Management Sales & Marketing Excellence through Digital Transformation Name of Entry Hong Kong TV Shopping Network Company Limited ThePlace - All-in-One eShop Solution Meiriki Japan Company Limited Meiriki Japna Digitalization and System Integration Swire Coca-Cola HK Digital Vending Ecosystem Supply Chain & Logistics Excellence through Digital Transformation Name of Entry Crown Gas Stoves (Holdings) Company Limited QR Code Product Tracking System DCH Auriga (Hong Kong) Limited Robotic warehousing with clinical order fulfillment via web portal PARKnSHOP PARKnSHOP Offers Customers with Seamless O+O Retail Experience, Unlocking Post-pandemic Growth with Launch of PNS Online Business Fulfilment Centre Rising Star of the Year Name of Entry LocoBike World's First True Green Mobility Solution Meat the Next Company Limited TIGA MILK - Sustainable Choice for social inclusion and well-being TriTerra Technology Limited Motivation Scheme for City Decarbonization Digital Transformation Enterprise of the Year(Grand Award) Name of Entry PARKnSHOP PARKnSHOP Offers Customers with Seamless O+O Retail Experience, Unlocking Post-pandemic Growth with Launch of PNS Online Business Fulfilment Centre About GS1 Hong Kong Founded by the Hong Kong General Chamber of Commerce in 1989, GS1 Hong Kong is the local chapter of GS1®. GS1 Hong Kong's mission is to empower businesses of their digital transformation, improve supply chain visibility and efficiency, ensure product authenticity, facilitate commerce connectivity and enable sustainable value chain through the provision of global supply chain standards (including GTIN & barcodes), and a full spectrum of platforms, solutions and services. GS1 Hong Kong currently supports close to 8,000 corporate members from 20 sectors including retail & consumer packaged goods, food & beverage and food services, healthcare, apparel & footwear, logistics & ICT. By working closely with communities of trading partners, industry organizations, government, and technology providers, we can foster a collaborative ecosystem, paving the way for "Smarter Business, Better Life". Headquartered in Brussels, Belgium, GS1® is a not-for-profit, standards organisation that has 118 national chapters serving 150 economies globally. For more information, please visit www.gs1hk.org.
SEOUL, South Korea, Nov. 1, 2024 /PRNewswire/ -- Fibocom (Stock code: 300638), a global leading provider of IoT (Internet of Things) wireless solutions and wireless communication modules, launches an LTE-only Cat 1bis module MG661-KR during the AIoT Korea Exhibition and Conference 2024, to accelerate the digital transformation of local IoT industries with high-performance, cost-effectiveness Cat 1bis wireless solution. The MG661-KR module is positioned to provide nationwide 4G connection to IoT devices such as asset trackers, mobile payment terminals, shared mobilities, industrial routers etc., enabling the massive IoT deployments across industries. The MG661-KR is developed from a dedicated Cat 1bis chipset platform that is compliant with the 3GPP Release 13 standard. By adopting the single antenna design, the module delivers data transmission rates of up to 10.3Mbps downlink and 5.1Mbps uplink under a 4G network while simplifying device design, reducing power consumption and lowering the device cost. Benefiting from the hardware simplification, the 4G-only MG661-KR is packaged at ultra-compact LGA form factor with a measurement of 17.7x15.8x2.4mm, allowing maximum flexibility for customers to develop the various IoT devices. Apart from the hardware configuration, the Cat 1bis module also integrates with rich network protocols and multiple universal interfaces, supports mainstream operating system drivers such as Windows, Android, Linux, to satisfy the diverse application demands in the IoT industry. Cat 1bis technology is growing as a powerful driving force to accelerate digital transformation in low and medium-speed IoT markets. And according to a new report from ABI Research, the Cat 1bis module is forecasted to replace nearly 70% of the Cat 1 market by 2029, stating a promising future of Cat 1bis technology in the IoT landscape. As many carriers sunset 2G and 3G networks to reallocate spectrum for 4G LTE and 5G, Cat 1bis plays a crucial role as a replacement technology for IoT applications that previously relied on 2G or 3G networks. Cat 1bis offers an affordable and efficient migration path for these devices, providing LTE-level connectivity without the need for 5G's advanced features or the high cost of Cat 4. The newly launched MG661-KR offers an ideal solution for IoT industry customers to implement the Cat 1bis technology to their devices without complex configurations and significantly ease investment concerns. The commercial sample of MG661-KR is available now, to learn more about Cat 1bis and its demos, welcome to visit Fibocom booth #G101 on the 3rd Floor of Hall D in COEX at the AIoT Korea from October 30 to November 1 2024. About Fibocom Fibocom is a global leading provider of wireless communication modules and solutions as well as the first wireless communication module provider listed on China A-shares stock market (stock code: 300638). Fibocom offers a one-stop solution for industry customers by integrating wireless communication modules and IoT solutions. With over two decades of engagement in M2M and IoT communication technology and extensive expertise, we are capable of bringing reliable, convenient, secure and intelligent connectivity service to every industry, enriching smart life with a perfect wireless experience. Fibocom's product portfolio ranges from cellular modules (5G/4G/3G/2G/LPWA), automotive-grade modules, AI modules, android-smart modules, GNSS modules and antenna service. Together, we aim to empower digital transformation across industries such as ACPC (Always Connected PC), mobile broadband, smart retail, C-V2X, robotics, smart energy, IIoT, smart cities, smart agriculture, smart home, telemedicine, etc. Find out the latest news at www.fibocom.com, and follow us on LinkedIn /X /Facebook /Youtube. Media Contact: pr@fibocom.com
CHANGSHA, China, Oct. 31, 2024 /PRNewswire/ -- Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion"; 1157.HK) has showcased the latest high-end intelligent agricultural machinery equipment products, advanced solutions and technological innovations to the 2024 China International Agricultural Machinery Exhibition held from October 26 to 28 in Changsha, China. Zoomlion Brings Latest Innovative Agricultural Solutions to 2024 China International Agricultural Machinery Exhibition Zoomlion's exhibition was the largest at the tradeshow, featuring over 70 best-selling products for diverse environments, including nine new high-end models, optimized for international markets, and a comprehensive series for the entire crop production process. At the Exhibition, Zoomlion released the TF220 combine harvester, which boasts the largest feeding capacity, horsepower, mowing width, and grain tank in the Chinese market. Along with harvesting crops such as corn, soybeans, and wheat, it also adopts the compound threshing and large area cleaning system that reduces seed loss to less than 0.6 percent while delivering high operation efficiency and reliability. Zoomlion also introduced the industry-leading 5HXQ-60 low-temperature double-cycle dryer, the DV3804 hybrid tractor with 380 horsepower, and PL80 crawler type harvester. Other key innovations in digital and smart agriculture showcased included the ZZBU-50 crop protection drone, ZLDAPR-001 fruit-picking robot, HEV500 hybrid tractor powertrain, and PL80 crawler-type harvester, along with essential components such as self-developed threshing drums and bus electric control valves. A Zoomlion dealer from Thailand noted at the Exhibition with Zoomlion's exceptional products and corporate strength, he has confidence in the partnership to develop more business in the local market. The intelligent agriculture section highlighted three precision systems of fertilizer application, irrigation and plant protection, IoT equipment, an on-site farm management platform, and a smart farming cloud application. By converging the mature construction machinery technologies of new energy, digitalization, and AI with agricultural equipment, Zoomlion has achieved numerous breakthroughs in the industry. To date, Zoomlion Smart Agriculture has served over ten million acres of land across China and supported agriculture development by leveraging digital core technologies of rice farming. In the past three years, Zoomlion's agricultural machinery overseas business has achieved continuous growth, with its products and services now covering over 60 countries and regions. "We are at the new beginning of shared development. With strong R&D, production process and manufacturing capabilities, I am confident we can achieve greater growth in the global agricultural machinery industry," said Lu Qing, assistant president of Zoomlion.
Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates during clinical trials, resulting in significant development costs Human-specific diseases cannot be accurately modeled by animals, leading to limited medical options or advancements This new study leverages the capabilities of artificial intelligence (AI) and machine learning (ML) to address the challenge of achieving automated and comprehensive "smart" drug screening using Medera's mini-Heart technology platform Innovative AI/ML-based model combines data from multiple human mini-Heart screening assays and takes advantage of the complementary strengths to achieve superior next-generation drug classification capabilities The unique combination of AI/ML and human mini-Hearts can accelerate drug discovery, clinical translation and precision medicine by improving screening efficiency, reducing costs, enhancing safety and creating new opportunities for patient benefits SUMMIT, N.J. and BOSTON, Mass., Oct. 31, 2024 /PRNewswire/ -- Medera Inc. ("Medera"), a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches, announced today the publication of a new study in the peer-reviewed journal Pharmacological Research (volume 209). This study, entitled "Enhanced Drug Classification Using Machine Learning with Multiplexed Cardiac Contractility Assays," demonstrates how Novoheart, Medera's wholly-owned preclinical subsidiary focused on human cardiovascular disease modeling for drug discovery, is leveraging AI and ML to improve next-generation drug screening processes. The present work aims to address a long-standing challenge in the pharmaceutical industry: accurately screening and classifying drug candidates for their effects on human heart function. By applying AI-driven automation, the objective is to enhance the success rates of future clinical trials and ultimately improve patient benefits by modernizing the drug development process. Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates (over 90%) during clinical trials, resulting in development costs that can exceed $2 billion per drug on average. Furthermore, human-specific diseases cannot be accurately modeled by animals, leading to limited medical options or advancements. Novoheart's present study demonstrates a novel approach utilizing AI/ML combined with comprehensive functional data from its various human mini-Heart assays, engineered from human pluripotent stem cell-derived cardiomyocytes, to create a more predictive and automated preclinical model of human cardiac responses. This innovative approach improves the accuracy of drug screening, promising to increase efficiency, reduce costs, and enhance safety of developing new drugs, thereby creating opportunities for drug developers and improving outcomes for patients. By testing three distinct proprietary engineered human mini-Heart assays, including our flagship human-heart-in-a-jar, specialized for measuring different cardiac characteristics, with a library of known compounds spanning a range of drug classes, the Novoheart research team generated a robust dataset encompassing electrophysiology and contractility parameters. The resulting ensemble AI-based algorithm achieved an impressive 86.2% predictive accuracy in classifying the effects of unknown compounds, surpassing prior ML methods for drug classification. This study is an expansion of the Company's patent-pending, single-assay ML technology as previously published. "By harnessing the power of machine learning in our suite of human-based mini-Heart assays, we are advancing the frontiers of preclinical drug development," stated Kevin Costa, Ph.D., Novoheart's Chief Scientific Officer and co-founder. "This innovation simplifies and improves the cardiac screening process for both our internal teams, partners and clients utilizing Novoheart's technology." "This innovative approach clearly outperforms traditional single-assay models and aligns with the objectives advocated in the FDA Modernization Act 2.0," stated Ronald Li, Ph.D., Medera's CEO and Founder. "The unique combination of AI/ML with human mini-Hearts can significantly accelerate drug discovery and screening, reduce costs, and improve precision by automating the analysis of very complex biological data. It can minimize the need for animal testing and enhance predictive toxicology, reducing the risk of late-stage failures, thereby increasing successes for drug developers and maximizing benefits for patients. Such a human-based AI approach also promotes precision medicine (by taking into consideration different genetic backgrounds or disease mutations) and optimization of formulations, leading to more effective and marketable therapies and improving patient safety throughout the drug development process." This AI/ML-based automation will be made commercially available via Novoheart's software and hardware platforms. Please direct any inquiries to sales@novoheart.com. On September 5, 2024, Medera and Keen Vision Acquisition Corporation ("KVAC") (Nasdaq: KVAC, KVACW), announced they had entered into a definitive merger agreement. About Medera Medera (www.medera.bio) is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat or currently incurable diseases with significant unmet needs, utilizing next-generation gene and cell-based approaches in combination with bioengineered human-based technology (including the mini-Heart platform). Medera operates via the two preclinical and clinical business units, Novoheart and Sardocor, respectively. Novoheart capitalizes on the world's first and award-winning "mini-Heart" Technology for revolutionary disease modelling and drug discovery, uniquely enabling the modelling of human-specific diseases and discovery of therapeutic candidates free from species-specific differences in accordance to the FDA Modernization Act 2.0. Novoheart's versatile technology platform provides a range of state-of-the-art automation hardware and software as well as screening services, for human-specific disease modelling, therapeutic target discovery and validation, drug toxicity and efficacy screening, and dosage optimization carried out in the context of healthy and/or diseased human heart chambers and tissues. Global pharmaceutical and academic leaders are using Novoheart's technology platform their drug discovery and development purposes. The Novoheart platform has facilitated and accelerated the development of Sardocor's lead therapeutic candidates that are currently in clinical trials. Sardocor is dedicated to the clinical development of novel next-generation therapies for Medera. Leveraging Novoheart's human-based drug discovery and validation platforms, Sardocor aims to expedite drug development and regulatory timelines for its gene and cell therapy pipeline. Sardocor has received Investigational New Drug (IND) clearances from the FDA for three ongoing AAV-based cardiac gene therapy clinical trials targeting Heart Failure with Reduced Ejection Fraction (HFrEF), Heart Failure with Preserved Ejection Fraction (HFpEF) with the Fast Track Designation, and Duchenne Muscular Dystrophy-induced Cardiomyopathy (DMD-CM) with the Orphan Drug Designation. Additionally, Sardocor's pipeline includes four preclinical gene therapy and three preclinical small molecule candidates targeting various cardiac, pulmonary, and vascular diseases. About Keen Vision Acquisition Corporation Keen Vision Acquisition Corp ("KVAC"), listed on Nasdaq, is a blank check company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. KVAC is focused on biotechnology, consumer goods or agriculture opportunities, which are also evaluated on their sustainability, environmental, social, and corporate governance ("ESG") imperatives. EF Hutton LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC, are serving as Capital Markets Advisors for KVAC. www.kv-ac.com Forward-Looking Statements Certain statements included in this press release are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release are forward-looking statements. Any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are also forward-looking statements. In some cases, you can identify forward-looking statements by words such as "estimate," "plan," "project," "forecast," "intend," "expect," "anticipate," "believe," "seek," "strategy," "future," "opportunity," "may," "target," "should," "will," "would," "will be," "will continue," "will likely result," "preliminary," or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements include, without limitation, KVAC's, Medera's, or their respective management teams' expectations concerning the outlook for their or Medera's business, productivity, plans, and goals for future operational improvements and capital investments, operational performance, future market conditions, or economic performance and developments in the capital and credit markets and expected future financial performance, including expected net proceeds, expected additional funding, the percentage of redemptions of KVAC's public shareholders, growth prospects and outlook of Medera' operations, individually or in the aggregate, including the achievement of project milestones, commencement and completion of commercial operations of certain of Medera's projects, as well as any information concerning possible or assumed future results of operations of Medera. Forward-looking statements also include statements regarding the expected benefits of the transactions contemplated by the merger ("Transaction"). The forward-looking statements are based on the current expectations of the respective management teams of Medera and KVAC, as applicable, and are inherently subject to uncertainties and changes in circumstance and their potential effects. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, (i) the risk that the Transaction may not be completed in a timely manner or at all, which may adversely affect the price of KVAC's securities; (ii) the risk that the Transaction may not be completed by KVAC's business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by KVAC; (iii) the failure to satisfy the conditions to the consummation of the Transaction, including the adoption of the Merger Agreement by the shareholders of KVAC and the receipt of certain regulatory approvals; (iv) market risks; (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; (vi) the effect of the announcement or pendency of the Transaction on Medera's business relationships, performance, and business generally; (vii) the outcome of any legal proceedings that may be instituted against Medera or KVAC related to the Merger Agreement or the Transaction; (viii) failure to realize the anticipated benefits of the Transaction; (ix) the inability to maintain the listing of KVAC's securities or to meet listing requirements and maintain the listing of Medera's securities on Nasdaq; (x) the inability to implement business plans, forecasts, and other expectations after the completion of the Transaction, identify and realize additional opportunities, and manage its growth and expanding operations; (xi) risks related to Medera's ability to develop, license or acquire new therapeutics; (xii) the risk that Medera will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; (xiii) the risk of product liability or regulatory lawsuits or proceedings relating to Medera's business; (xiv) uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; (xv) risks related to regulatory review, and approval and commercial development; (xvi) risks associated with intellectual property protection; (xvii) Medera's limited operating history and risk that it may never successfully commercialise its products; (xviii) Medera expects to continue to incur significant losses and may never achieve or maintain profitability; and (xix) the risk that additional financing in connection with the Transaction may not be raised on favorable terms. The foregoing list is not exhaustive, and there may be additional risks that neither KVAC nor Medera presently knows or that KVAC and Medera currently believe are immaterial. You should carefully consider the foregoing factors, any other factors discussed in this press release and the other risks and uncertainties described in the "Risk Factors" section of KVAC's Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 29, 2024, the risks to be described in the registration statement, which will include a preliminary proxy statement/prospectus, and those discussed and identified in filings made with the SEC by KVAC from time to time. Medera and KVAC caution you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth in this press release speak only as of the date of this press release. Neither Medera nor KVAC undertakes any obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs. In the event that any forward-looking statement is updated, no inference should be made that Medera or KVAC will make additional updates with respect to that statement, related matters, or any other forward-looking statements. Any corrections or revisions and other important assumptions and factors that could cause actual results to differ materially from forward-looking statements, including discussions of significant risk factors, may appear, up to the consummation of the Transaction, in KVAC's public filings with the SEC, and which you are advised to review carefully. Important Information for Investors and Shareholders In connection with the Transaction, KVAC and Medera filed a registration statement with the SEC, which includes a prospectus with respect to the securities to be issued in connection with the Transaction and a proxy statement to be distributed to holders of KVAC's common shares in connection with KVAC's solicitation of proxies for the vote by KVAC's shareholders with respect to the Transaction and other matters to be described in the Registration Statement (the "Proxy Statement"). After the SEC declares the registration statement effective, KVAC plans to mail copies to shareholders of KVAC as of a record date to be established for voting on the Transaction. This press release does not contain all the information that should be considered concerning the Transaction and is not a substitute for the registration statement, Proxy Statement or for any other document that KVAC may file with the SEC. Before making any investment or voting decision, investors and security holders of KVAC are urged to read the registration statement and the Proxy Statement, and any amendments or supplements thereto, as well as all other relevant materials filed or that will be filed with the SEC in connection with the Transaction as they become available because they will contain important information about, Medera, KVAC and the Transaction. Investors and security holders will be able to obtain free copies of the registration statement, the Proxy Statement and all other relevant documents filed or that will be filed with the SEC by KVAC through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by KVAC may be obtained free of charge from KVAC's website at https://www.kv-ac.com or by directing a request to info@kv-ac.com. The information contained on, or that may be accessed through, the websites referenced in this press release is not incorporated by reference into, and is not a part of, this press release. Participants in the Solicitation KVAC, Medera and their respective directors, executive officers and other members of management and employees may, under the rules of the SEC, be deemed to be participants in the solicitations of proxies in connection with the Transaction. For more information about the names, affiliations and interests of KVAC's directors and executive officers, please refer to KVAC's annual report on Form 10-K filed with the SEC on March 29, 2024, which can be found at https://www.sec.gov/ix?doc=/Archives/edgar/data/1889983/000121390024027973/ea0201104-10k_keenvision.htm and registration statement, Proxy Statement and other relevant materials filed with the SEC in connection with the Transaction when they become available. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, which may, in some cases, be different than those of KVAC's shareholders generally, will be included in the registration statement and the Proxy Statement and other relevant materials when they are filed with the SEC when they become available. Shareholders, potential investors and other interested persons should read the registration statement and the Proxy Statement and other such documents carefully, when they become available, before making any voting or investment decisions. You may obtain free copies of these documents from the sources indicated above. No Offer or Solicitation This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in the Transaction shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
A12 藝術空間
Agriculture
請先登入後才能發佈新聞。
還不是會員嗎?立即 加入台灣產經新聞網會員 ,使用免費新聞發佈服務。 (服務項目) (投稿規範)